Firma ViGeneron, Autor bei News-Research

Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology

25. Oktober 202326. Oktober 2023 Firma ViGeneronPosted in Forschung und EntwicklungTagged aav, abca4, brain, crispr, Packaging, patients, pigmentosa, retinal, retinitis, stargardt, trans, vg801, vg901, vigeneron, with

REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissues Potential to address prevalent inherited diseases caused […]

ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa

22. August 202322. August 2023 Firma ViGeneronPosted in Forschung und EntwicklungTagged aav, atu, can, clinical, cng, eyesight, its, ocular, patients, pigmentosa, retinal, retinitis, vg901, vgaav, vigeneron

ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, today announced that the European Medicines Agency (EMA) has approved the Clinical Trial Application (CTA) for VG901, a potentially transformative gene therapy […]

ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

11. Oktober 202211. Oktober 2022 Firma ViGeneronPosted in Forschung und EntwicklungTagged aav, cell, cells, Packaging, patients, pigmentosa, retinal, retinitis, stargardt, trans, vg901, vgaav, vigeneron, vigenerons, with

Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage […]

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

26. April 202226. April 2022 Firma ViGeneronPosted in Kooperationen / FusionenTagged cells, daiichi, financial, injection, new, patients, research, retinal, sankyo, therapy, treatment, vgaav, vigeneron, vigenerons, with

ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to […]

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

6. April 2022 Firma ViGeneronPosted in Forschung und EntwicklungTagged aav, cells, clinical, cns, injection, ophthalmic, patients, Payment, retinal, Royalties, therapy, vgaav, vigeneron, vigenerons, with

Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is […]

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

18. Januar 202112. April 2021 Firma ViGeneronPosted in Forschung und EntwicklungTagged cells, collateral, daiichi, financial, injection, medical, ophthalmic, patients, research, sankyo, therapy, treatment, vigeneron, vigenerons, with

ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a […]

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

5. Januar 202112. April 2021 Firma ViGeneronPosted in MedizintechnikTagged aav, cells, clinical, medical, patients, Payment, poc, research, retinal, Royalties, therapy, vgaav, vigeneron, vigenerons, with

. – Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target – The companies will use ViGeneron’s proprietary […]

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

1. Dezember 202012. April 2021 Firma ViGeneronPosted in Kooperationen / FusionenTagged aav, apptec, atu, cell, cells, market, ophthalmic, patients, pigmentosa, retinal, retinitis, vgaav, vigeneron, vigenerons, with

ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for […]